Shared on 07 Dec 25

Fair value Increased 0.062%

MEDP: Biotech Funding Recovery And Book-To-Bill Trends Will Shape Future Outlook

Analysts have nudged their price target on Medpace Holdings modestly higher by about $2 per share to reflect increased confidence in a sustained recovery in biotech funding, healthier book to bill trends, and signs that contract research organization demand has likely stabilized. Analyst Commentary Recent Street research reflects a more constructive stance on Medpace, with several bullish analysts lifting price targets to account for stronger sector fundamentals and improved visibility into the company’s growth trajectory.

Shared on 22 Nov 25

Fair value Increased 3.64%

MEDP: Improving Biotech Pipeline And Book-To-Bill Trends Will Support Recovery Momentum

The analyst price target for Medpace Holdings has increased from $519 to $538. Analysts cite improving Biotech market confidence and stronger forward earnings projections as factors supporting this upward revision.

Shared on 07 Nov 25

Fair value Increased 14%

MEDP: Below-Normal Bookings In 2025 Will Pressure Revenue Expansion

Analysts have raised their price target for Medpace Holdings from $456 to approximately $519, citing higher growth estimates and renewed confidence in the CRO sector's recovery. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for Medpace, citing increased confidence in the recovery trajectory of the biotech sector and the broader contract research organization market.

Shared on 24 Oct 25

Fair value Increased 6.54%

Analysts have raised their fair value estimate for Medpace Holdings to $456 from $428 per share. This change reflects updated optimism based on recent price target adjustments and expectations for stabilization in contract research organization demand trends.

Shared on 09 Oct 25

Fair value Increased 1.03%

Analysts have raised Medpace Holdings’ fair value estimate modestly, from $423.64 to $428.00. Industry views reflect improved biotech funding and solid bookings, although some ongoing uncertainty in demand signals remains.

Shared on 04 Sep 25

Fair value Increased 0.32%

As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).

Shared on 07 May 25

Fair value Increased 41%

Shared on 30 Apr 25

Fair value Decreased 16%

AnalystConsensusTarget has decreased revenue growth from 6.1% to 5.1% and decreased future PE multiple from 21.6x to 18.9x.

Shared on 23 Apr 25

Fair value Decreased 8.03%

AnalystConsensusTarget has decreased revenue growth from 7.2% to 6.1% and decreased future PE multiple from 25.0x to 21.6x.

Shared on 16 Apr 25

Fair value Increased 4.35%

AnalystConsensusTarget has decreased revenue growth from 8.0% to 7.2% and decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 09 Apr 25

Fair value Increased 22%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 12%

Shared on 26 Mar 25

Fair value Decreased 0.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 14%

AnalystConsensusTarget has decreased revenue growth from 9.0% to 8.1%.

Future Sector Demand Shifts Will Influence Risk And Reward Dynamics

MEDP: Biotech Funding Recovery And Book-To-Bill Trends Will Shape Future Outlook

MEDP: Improving Biotech Pipeline And Book-To-Bill Trends Will Support Recovery Momentum

MEDP: Below-Normal Bookings In 2025 Will Pressure Revenue Expansion

Shared on 24 Oct 25

Shared on 09 Oct 25

Shared on 04 Sep 25

Shared on 07 May 25

Shared on 30 Apr 25

Shared on 23 Apr 25

Shared on 16 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 19 Mar 25

Shared on 10 Mar 25